PE20142444A1 - NEW COMPOSITION OF ALPHENTANIL FOR THE TREATMENT OF ACUTE PAIN - Google Patents
NEW COMPOSITION OF ALPHENTANIL FOR THE TREATMENT OF ACUTE PAINInfo
- Publication number
- PE20142444A1 PE20142444A1 PE2014001937A PE2014001937A PE20142444A1 PE 20142444 A1 PE20142444 A1 PE 20142444A1 PE 2014001937 A PE2014001937 A PE 2014001937A PE 2014001937 A PE2014001937 A PE 2014001937A PE 20142444 A1 PE20142444 A1 PE 20142444A1
- Authority
- PE
- Peru
- Prior art keywords
- alfentanil
- acid
- microparticles
- treatment
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referida a una composicion farmaceutica para administracion sublingual, asi como la liberacion rapida de alfentanilo de la misma y/o la rapida captacion de alfentanilo a traves de la mucosa oral, que comprende: a) microparticulas de alfentanilo, o una sal farmaceuticamente aceptable del mismo, presentandose las microparticulas en las superficies de particulas vehiculo mas grandes, b) una base debil soluble en agua y c) un compuesto que es un acido debil, presentandose el acido en mezcla intima con las microparticulas de alfentanilo o la sal del mismo, presentandose en el interior de las particulas vehiculo, de forma que dichas particulas vehiculo comprenden un compuesto de dicho material acido y otro material de particula vehiculo o sobre las superficies de las particulas. La composicion puede comprender ademas un disgregante. El acido es acido citrico. Dicha composicion es util en el tratamiento del dolorReferring to a pharmaceutical composition for sublingual administration, as well as the rapid release of alfentanil therefrom and / or the rapid uptake of alfentanil through the oral mucosa, comprising: a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof , presenting the microparticles on the surfaces of larger vehicle particles, b) a weak base soluble in water and c) a compound that is a weak acid, the acid being presented in intimate mixture with the microparticles of alfentanil or its salt, presenting in the interior of the carrier particles, such that said carrier particles comprise a compound of said acidic material and another carrier particle material or on the surfaces of the particles. The composition may further comprise a disintegrant. The acid is citric acid. This composition is useful in the treatment of pain
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207701.2A GB201207701D0 (en) | 2012-05-02 | 2012-05-02 | New pharmaceutical composition |
| GBGB1221130.6A GB201221130D0 (en) | 2012-11-23 | 2012-11-23 | New pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142444A1 true PE20142444A1 (en) | 2015-01-09 |
Family
ID=48577134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001937A PE20142444A1 (en) | 2012-05-02 | 2013-05-01 | NEW COMPOSITION OF ALPHENTANIL FOR THE TREATMENT OF ACUTE PAIN |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US8815911B2 (en) |
| EP (2) | EP3150199B1 (en) |
| JP (1) | JP6275696B2 (en) |
| KR (1) | KR20150005695A (en) |
| CN (1) | CN104427978B (en) |
| AU (1) | AU2013255640B2 (en) |
| BR (1) | BR112014027213A8 (en) |
| CA (1) | CA2871805A1 (en) |
| CL (1) | CL2014002979A1 (en) |
| CO (1) | CO7170181A2 (en) |
| CY (2) | CY1118570T1 (en) |
| DK (2) | DK3150199T3 (en) |
| EA (1) | EA028110B1 (en) |
| ES (2) | ES2694644T3 (en) |
| HK (1) | HK1203399A1 (en) |
| HR (2) | HRP20161634T1 (en) |
| HU (1) | HUE031792T2 (en) |
| IL (1) | IL235272B (en) |
| IN (1) | IN2014MN02156A (en) |
| LT (2) | LT3150199T (en) |
| ME (1) | ME02644B (en) |
| MX (1) | MX360665B (en) |
| NZ (1) | NZ701428A (en) |
| PE (1) | PE20142444A1 (en) |
| PH (1) | PH12014502407A1 (en) |
| PL (2) | PL2849730T3 (en) |
| PT (2) | PT3150199T (en) |
| RS (2) | RS57951B1 (en) |
| SG (1) | SG11201407081PA (en) |
| SI (2) | SI3150199T1 (en) |
| SM (1) | SMT201700086B (en) |
| TR (1) | TR201815935T4 (en) |
| WO (1) | WO2013164620A1 (en) |
| ZA (1) | ZA201407559B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939569A1 (en) | 2011-09-19 | 2022-01-19 | Orexo AB | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| ES2694644T3 (en) * | 2012-05-02 | 2018-12-26 | Orexo Ab | New composition of alfentanil for the treatment of acute pain |
| WO2017180659A1 (en) * | 2016-04-11 | 2017-10-19 | Arizona Board Of Regents On Behalf Of University Of Arizona | Opioid receptor modulators |
| JP7023054B2 (en) * | 2017-04-05 | 2022-02-21 | 東和薬品株式会社 | Levetiracetam-containing pharmaceutical composition and method for producing the same |
| CN115047109B (en) * | 2022-06-17 | 2024-05-31 | 三明海关综合技术服务中心 | Method for detecting novel fentanyl mental active substances in food |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| DE19749724A1 (en) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Use of a combination of opioid and alpha-adrenergic agonist in pain relievers |
| SE9803239D0 (en) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| SE9803240D0 (en) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| JP4850346B2 (en) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | Mucosal patch |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| ATE329594T1 (en) | 2003-01-31 | 2006-07-15 | Orexo Ab | FAST-ACTING PHARMACEUTICAL COMPOSITION |
| EP1599186B1 (en) | 2003-02-24 | 2013-04-10 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| US20070036853A1 (en) | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| AU2004311879B2 (en) | 2003-12-31 | 2010-08-05 | Cima Labs Inc. | Effervescent oral opiate dosage form |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| EP1708686B1 (en) | 2003-12-31 | 2011-02-16 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| FR2883179B1 (en) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | COATED TABLET |
| US20080248110A1 (en) | 2005-03-28 | 2008-10-09 | Anders Pettersson | Pharmaceutical Compositions Useful in the Treatment of Pain |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| US20100233257A1 (en) | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| ES2577390T3 (en) * | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Transmucosal administration devices with greater uptake |
| WO2008068471A1 (en) * | 2006-12-04 | 2008-06-12 | Orexo Ab | New non-abusable pharmaceutical composition comprising opioids |
| EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| CA2704929C (en) | 2007-08-07 | 2018-05-15 | Pamela Palmer | Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms |
| US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
| US8343978B2 (en) | 2008-08-04 | 2013-01-01 | Adds Pharmaceuticals Llc | Fast onset orodispersable tablets |
| US20100056574A1 (en) | 2008-09-04 | 2010-03-04 | Mallinckrodt Inc. | Crystalline Forms of Sufentanil |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| MX2011012043A (en) | 2009-05-13 | 2012-03-29 | Protein Delivery Solutions Llc | Pharmaceutical system for trans-membrane delivery. |
| WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
| JP2009280611A (en) * | 2009-08-26 | 2009-12-03 | Kyukyu Yakuhin Kogyo Kk | Film preparation for oral mucosa |
| US20110091544A1 (en) | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| ES2694644T3 (en) * | 2012-05-02 | 2018-12-26 | Orexo Ab | New composition of alfentanil for the treatment of acute pain |
-
2013
- 2013-05-01 ES ES16197166.8T patent/ES2694644T3/en active Active
- 2013-05-01 LT LTEP16197166.8T patent/LT3150199T/en unknown
- 2013-05-01 PT PT16197166T patent/PT3150199T/en unknown
- 2013-05-01 SI SI201331238T patent/SI3150199T1/en unknown
- 2013-05-01 IN IN2156MUN2014 patent/IN2014MN02156A/en unknown
- 2013-05-01 DK DK16197166.8T patent/DK3150199T3/en active
- 2013-05-01 MX MX2014013176A patent/MX360665B/en active IP Right Grant
- 2013-05-01 JP JP2015509496A patent/JP6275696B2/en not_active Expired - Fee Related
- 2013-05-01 RS RS20181295A patent/RS57951B1/en unknown
- 2013-05-01 PE PE2014001937A patent/PE20142444A1/en not_active Application Discontinuation
- 2013-05-01 TR TR2018/15935T patent/TR201815935T4/en unknown
- 2013-05-01 SI SI201330490A patent/SI2849730T1/en unknown
- 2013-05-01 NZ NZ701428A patent/NZ701428A/en not_active IP Right Cessation
- 2013-05-01 BR BR112014027213A patent/BR112014027213A8/en not_active Application Discontinuation
- 2013-05-01 DK DK13727314.0T patent/DK2849730T3/en active
- 2013-05-01 AU AU2013255640A patent/AU2013255640B2/en not_active Ceased
- 2013-05-01 EA EA201401200A patent/EA028110B1/en not_active IP Right Cessation
- 2013-05-01 WO PCT/GB2013/051131 patent/WO2013164620A1/en active Application Filing
- 2013-05-01 US US13/874,762 patent/US8815911B2/en not_active Expired - Fee Related
- 2013-05-01 KR KR1020147033700A patent/KR20150005695A/en not_active Application Discontinuation
- 2013-05-01 ES ES13727314.0T patent/ES2614757T3/en active Active
- 2013-05-01 ME MEP-2017-9A patent/ME02644B/en unknown
- 2013-05-01 PL PL13727314T patent/PL2849730T3/en unknown
- 2013-05-01 CA CA2871805A patent/CA2871805A1/en not_active Abandoned
- 2013-05-01 EP EP16197166.8A patent/EP3150199B1/en active Active
- 2013-05-01 HU HUE13727314A patent/HUE031792T2/en unknown
- 2013-05-01 PT PT137273140T patent/PT2849730T/en unknown
- 2013-05-01 PL PL16197166T patent/PL3150199T3/en unknown
- 2013-05-01 EP EP13727314.0A patent/EP2849730B1/en active Active
- 2013-05-01 CN CN201380022630.2A patent/CN104427978B/en not_active Expired - Fee Related
- 2013-05-01 SG SG11201407081PA patent/SG11201407081PA/en unknown
- 2013-05-01 LT LTEP13727314.0T patent/LT2849730T/en unknown
- 2013-05-01 RS RS20161161A patent/RS55489B1/en unknown
-
2014
- 2014-07-15 US US14/331,507 patent/US9345698B2/en not_active Expired - Fee Related
- 2014-10-17 ZA ZA2014/07559A patent/ZA201407559B/en unknown
- 2014-10-22 IL IL235272A patent/IL235272B/en not_active IP Right Cessation
- 2014-10-27 PH PH12014502407A patent/PH12014502407A1/en unknown
- 2014-10-29 CO CO14239767A patent/CO7170181A2/en not_active Application Discontinuation
- 2014-11-03 CL CL2014002979A patent/CL2014002979A1/en unknown
-
2015
- 2015-04-28 HK HK15104088.8A patent/HK1203399A1/en not_active IP Right Cessation
-
2016
- 2016-04-26 US US15/138,570 patent/US9782396B2/en not_active Expired - Fee Related
- 2016-12-05 HR HRP20161634TT patent/HRP20161634T1/en unknown
-
2017
- 2017-01-31 CY CY20171100139T patent/CY1118570T1/en unknown
- 2017-02-08 SM SM201700086T patent/SMT201700086B/en unknown
- 2017-09-11 US US15/701,300 patent/US20180214437A1/en not_active Abandoned
-
2018
- 2018-10-25 HR HRP20181761TT patent/HRP20181761T1/en unknown
- 2018-11-05 CY CY181101154T patent/CY1120820T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142444A1 (en) | NEW COMPOSITION OF ALPHENTANIL FOR THE TREATMENT OF ACUTE PAIN | |
| EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
| PE20180522A1 (en) | ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT | |
| PE20141171A1 (en) | ORAL PHARMACEUTICAL DOSAGE FORM RESISTANT TO ALTERATION INCLUDING OPIOID AGONIST AND OPIOID ANTAGONIST | |
| EA201491285A1 (en) | IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID | |
| EA201400246A1 (en) | NEW, NOT ALLOWING ABUSE USING PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE | |
| AR095160A1 (en) | ALTERATION PROOF PHARMACEUTICAL FORMULATIONS | |
| MX2015016421A (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease. | |
| CL2017003066A1 (en) | Compositions of amorphous calcium carbonate for administration by inhalation, sublingual or buccal | |
| AR091351A1 (en) | BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING | |
| IN2015DN03921A (en) | ||
| DOP2014000269A (en) | NEW DOSAGE AND FORMULATION | |
| UY31826A (en) | PEPTIDE COMPOUND AND ITS USE | |
| CL2015001940A1 (en) | Formulation comprising a benzothiazolone compound. | |
| UY37518A (en) | DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING | |
| PE20151282A1 (en) | COMBINATION OF MEDICINES INCLUDING PHENYLPHRINE AND PARACETAMOL | |
| CO6410284A2 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES | |
| DOP2013000004A (en) | THERAPEUTIC AGENTS 976 | |
| ECSP17008187A (en) | PHARMACEUTICAL DOSAGE FORMS | |
| BR112015003761A2 (en) | compound, pharmaceutical composition, dosage unit form, method for administering a biologically active agent and method for preparing a composition | |
| AR128434A2 (en) | COMPOSITIONS AND METHODS OF TRANSMUCOUS ABSORPTION | |
| AR087155A1 (en) | GRANULATED FORMULATION OF AZAPERONE OF FAST DISSOLUTION | |
| TH167686B (en) | A combination drug substance containing phenylphine and paracetamol. | |
| BR112014028864A2 (en) | dosage and formulation | |
| AR100910A1 (en) | ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |